[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369968-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369968-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recent-advances-in-the-applications-of-biomaterials-in-ovarian-cancer","Recent Advances in the Applications of Biomaterials in Ovarian Cancer","","Ovarian cancer remains the most fatal gynecological malignancy, with poor survival despite progress in modern medicine. Late diagnosis, driven by nonspecific early symptoms and limited screening, contributes to high mortality, while molecular, histological, and anatomical heterogeneity complicates universally effective therapies. This review synthesizes how biomaterials are applied across diagnosis, treatment, and screening, emphasizing biomimetic materials that improve functionality, enable enhanced imaging, and support biosensors and tumor organoids, while outlining key challenges and future directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recent-advances-in-the-applications-of-biomaterials-in-ovarian-cancer/369968/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recent-advances-in-the-applications-of-biomaterials-in-ovarian-cancer/369968.png","ImageObject",300,407,{"name":42,"@type":43},"awa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is ovarian cancer difficult to diagnose early?","Question",{"text":63,"@type":64},"Early-stage disease often presents with mild, vague, or asymptomatic symptoms, and sensitive screening methods are lacking, leading to late diagnosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations exist in current ovarian cancer treatment?",{"text":68,"@type":64},"Standard approaches such as cytoreduction surgery and platinum-based chemotherapy have initial responses, but recurrence is common and is frequently accompanied by chemoresistance.",{"name":70,"@type":61,"acceptedAnswer":71},"How do biomaterials contribute to ovarian cancer diagnosis and treatment?",{"text":72,"@type":64},"Biomaterials are used for diagnosis, treatment, and screening, can help bypass obstacles of traditional chemotherapy, enhance imaging, and support next-generation biosensors and tumor organoids.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369968,1790237910,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":109,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nRecent Advances in the Applications of Biomaterials in Ovarian Cancer  \nA M U B Mahfuz 1, Amol V. Janorkar 1, Rodney P. Rocconi 2 and Yuanyuan Duan 1, *  \nAcademic Editor: Hermann Ehrlich  \nReceived: 23 September 2025  \nRevised: 16 October 2025  \nAccepted: 3 November 2025  \nPublished: 12 November 2025  \nCitation: Mahfuz, A.M.U.B.; Janorkar, A.V.; Rocconi, R.P.; Duan, Y. Recent Advances in the Applications of Biomaterials in Ovarian Cancer. Biomimetics 2025, 10, 768 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biomimetics10110768  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Biomedical Materials Science, University of Mississippi Medical Center,  \nJackson, MS 39216, USA; [amahfuz@umc.edu](amahfuz@umc.edu) (A.M.U.B.M.); [ajanorkar@umc.edu](ajanorkar@umc.edu) (A.V.J.)  \n2 Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA; [rocconi@umc.edu](rocconi@umc.edu)  \n* [Correspondence: yduan@umc.edu](Correspondence: yduan@umc.edu)  \nAbstract  \nAmong the gynecological cancers, ovarian cancer is the most fatal. Despite advancements in modern medicine, the survival rate is abysmally low among ovarian cancer patients. Ovarian cancer poses several unique challenges, like late diagnosis due to the initial vagueness of the symptoms and lack of effective screening protocols. Recently, biomaterials have been explored and utilized extensively for the diagnosis, treatment, and screening of ovarian malignancies. Biomaterials can help bypass the obstacles of traditional chemotherapy and enhance imaging capabilities. They are also indispensable for next-generation biosensors and tumor organoids. Biomaterials inspired by biomimetic strategies that replicate the structural, chemical, and functional properties of natural biological systems have proven to have better functionalities. While numerous review articles have examined biomaterials in oncology, there is a lack of reviews dedicated specifically to their applications in ovarian cancer. This review aims to address this critical gap by providing the first comprehensive overview of the current biomaterial research on ovarian cancer and highlighting key challenges, opportunities, and future directions in this evolving interdisciplinary field.  \nKeywords: biomaterial; nanomaterial; ovarian cancer; drug delivery; tumor diagnosis  \n1. Introduction  \nIn today’s world, ovarian cancer is responsible for the highest mortality among women suffering from gynecological cancers. In 2022 alone, 324,398 new ovarian cancer patients were diagnosed, and 206,839 women died of ovarian cancer worldwide [1] . In spite of the recent advances achieved in modern medicine, the 5-year survival rate for this cancer is dismally low, particularly among cases diagnosed at advanced stages (≤20% for stage III and IV) . The asymptomatic, mildly symptomatic, or vaguely symptomatic nature of the early-stage disease and the absence of sensitive screening methods are responsible for late diagnosis and subsequent high mortality. Almost 80% of patients reach stage III or IV when they are diagnosed [2] . Furthermore, the heterogeneity of ovarian cancer at the molecular, histological, and anatomical levels presents significant challenges in designing universally effective treatments [3] . Standard therapeutic approaches include cytoreduction surgeries and adjuvant platinum-based chemotherapy. Although they initially offer good response rates, recurrence is common and often accompanied by chemoresistance [4] . This necessitates newer therapies and approaches with superior efficacy for early diagnosis and minimizing off-target effects.  \nOva","cbCaioCyFcneDEGp","https://ap.wps.com/l/cbCaioCyFcneDEGp","pdf",5816802,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Burden and challenges of ovarian cancer\n## Disease development and classification\n## Risk factors and symptom patterns\n## Molecular subtypes and clinical behavior","[{\"question\":\"Why is ovarian cancer difficult to diagnose early?\",\"answer\":\"Early-stage disease often presents with mild, vague, or asymptomatic symptoms, and sensitive screening methods are lacking, leading to late diagnosis.\"},{\"question\":\"What limitations exist in current ovarian cancer treatment?\",\"answer\":\"Standard approaches such as cytoreduction surgery and platinum-based chemotherapy have initial responses, but recurrence is common and is frequently accompanied by chemoresistance.\"},{\"question\":\"How do biomaterials contribute to ovarian cancer diagnosis and treatment?\",\"answer\":\"Biomaterials are used for diagnosis, treatment, and screening, can help bypass obstacles of traditional chemotherapy, enhance imaging, and support next-generation biosensors and tumor organoids.\"}]","Recent Advances in the Applications of Biomaterials in Ovarian Cancer | PDF",1790185868,101,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd83cacea3fe6bb5fa3be28a8eabe7aa.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdb84fb9651d64c475028dfe0790b569.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82ddfd47902df1bc1065a0638abfaad9.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/606d00137aaede424a83caea3aaf2d6b.webp",980,1385]